Harvard Business Review

JUNE 8, 2015

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. Experimentation is vital.

Health Care 8

Health Care Venture Capitalist Strategic Fit Pharmaceuticals 8

Harvard Business Review

APRIL 15, 2015

million industrial robots are in use or available in various industries including automotive, electronics, rubber and plastics, cosmetics, pharmaceutical, and food and beverage. Their market value is $9.5 Imagine: Future robots could be built to include a kind of ethical clause that limits what they are allowed to do.

Definition 8

Definition Ethics Industry Automotive 8

Harvard Business Review

NOVEMBER 5, 2015

As a child I felt no particular interest in pharmaceuticals, telecommunications, computers, oil and gas, health and beauty aids, medical devices, airlines, or shipbuilding, all of which I’ve simulated or war-gamed. I wonder what makes people market products that they know cause addiction and death. Then they grow up.

Career 8

Career Seminar Self-aware Telecommunications 8

Harvard Business Review

JANUARY 15, 2013

Business will move the great masses of humanity forward with advancements in pharmaceuticals, materials, process, and technology — but it will almost always leave 10% behind. Even social business will not address those issues for which markets cannot be developed. Philanthropy is the market for love. This we call ethics.

Learning Curve 9

Learning Curve Advertising GDP Pharmaceuticals 9

Harvard Business Review

SEPTEMBER 15, 2014

As Linda Hill and her colleagues have described, the company needed expert knowledge as it navigated the technically and ethically challenging waters of pharmaceutical development and marketing. In 2008, Pfizer was struggling with an unwieldy and costly model of obtaining outside legal help.

Gilbert 9

Gilbert Participative Cooper Network Economy 9

Harvard Business Review

MARCH 24, 2011

Competitors whispered that Gupta was committing the most un-McKinsey-like of sins: cutting price to get into new markets. As the stock market began to take off, though, and options rained down on corporate execs, the compensation tables began to turn, certainly for the top ranks.

McKinsey 14

McKinsey Consultative Waterman Intellectual Capital 14

Harvard Business Review

NOVEMBER 28, 2017

One of your executives comes to you with a proposal: she wants to lower the quality of service at the restaurants, reduce product safety standards, use deceptive marketing practices, lower employee pay, and adopt worse environmental practices. Why do anti-profit beliefs persist in a market society? Our research.

Company 8

Company Short-term Long-term Price 8

Harvard Business Review

SEPTEMBER 19, 2016

This logic and the institutions that reinforce it, like competitive markets and the rule of law, have transformed the world and lifted billions of people from poverty. Imagine, for example, that you’re a pharmaceutical CEO deciding whether to recall a new drug. How should you make this decision?

ROI 8

ROI Long-term Conflict of Interest Pharmaceuticals 8

Harvard Business Review

JANUARY 10, 2013

initiative — prohibitions against off-label marketing under the False Claims Act — swept through the pharmaceutical industry. The most notable was Fannie Mae's $10.8 billion restatement. In another instance, a new enforcement. The largest payments were from Pfizer ($2.3 billion) and GlaxoSmithKline ($3 billion).

Finance 8

Finance Banking Press Release Pharmaceuticals 8

Harvard Business Review

FEBRUARY 3, 2017

The business model of research-based pharmaceutical companies is under significant pressure. This strategy will tap potential growth in emerging markets, limit the risks of misconduct, and improve public trust in the industry. However, it also reflects stronger pressures to lower medicine costs in traditional pharmaceutical markets.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8